企业新闻


September 18, 2026

赛动智造以产线变革推动生物制造产业升级,践行国家智能制造战略引领

近日,全国先进制造业大会传达习近平总书记重要指示,强调要坚持智能化、绿色化、融合化方向,持续做大做强先进制造业,以新一代智能制造为主攻方向,纵深推进“人工智能+制造”,提升产业链自主可控水平,加快构建以先进制造业为骨干的现代化产业体系。(习近平就发展先进制造业作出重要指示) 对“生物+智造”而言,细胞治疗、放射性药物、病毒研究与实验自动化,正从“实验室工艺”走向“工业级智造”。作为细胞产业关键共性技术国家工程研究中心先进智造平台建设平台,赛动智造把国家政策要求拆解为三条可落地路线:以智能装备替代人工经验,以数智化贯通合规追溯,以国产核心模块保障产业链安全。 一、对标“智能化”:细胞智造从手工制备走向无人产线 总书记指出,要更加注重数智赋能,推动制造业智能化发展。 细胞产业长期受困于手工制备效率低、批次差异大、人员依赖强。赛动的解法是“硬件自动化+软件数字化+工艺模块化”一体推进。 依托细胞产业国家工程中心先进智造平台,赛动发布全自动细胞智造系统及无人细胞智造产线,覆盖矩阵式培养、智能配液、全自动细胞处理、密闭分装与全生命周期管理:Neo通过AI与数字孪生对细胞状态、培养环境、关键质量属性进行实时判断和预测,用CELLALL等智能软件实现从样本到患者的全程数据闭环;模块化产线可适配床边小批量“一人一批”,也可支撑CDMO/药企大批量并行,做到智能排产、多工艺兼容、远程审核。 公开交付案例中,赛动已向细胞行业领军企业部署的全自动细胞智造系统长期运行,累计完成百余批次生产制备;对比显示,洁净厂房与设备投入、人员管理成本显著下降。这说明细胞制剂的生产制造不只是“买几台设备”,而是用智能制造重构生产组织方式。 二、对标“自主化”:核药智造补上放射性药物装备短板 指示要求技术路线更加注重高端自主、提升产业链自主可控水平。核药具有半衰期短、辐射防护要求高、分装剂量严、人工操作风险大等特点,核心分装与排产装备长期是产业瓶颈。 赛动全自动核药分装仪面向核药房、放射性药物企业与医院核医学科,突破高精度全自动分装、智能动态排产、实时活度检测与热室集成等关键环节。该设备是国内通过国家药监局现场审查的国产原研全自动核药分装产品,已在多地核药企业/核药房装配交付;相关全自动核药房方案可提升运行效率、缩短产线建设周期,并降低人工职业暴露与半自动产线风险。 在《医用同位素中长期发展规划》和“十四五”医疗装备高端化背景下,赛动把核药分装、配液、排产、追溯做成国产软硬件一体方案,本质是把放射性药物“自主供应—自主生产—自主配送”的链条用智能制造守住。 三、对标“融合化”:病毒实验自动化工作站打通BT+AT+IT 先进制造业强调跨界融合、人工智能+制造深度融合。病毒相关研究对生物安全、无菌密闭、试剂配制、样本处理、分装留样和数据追溯要求极高。赛动将细胞与核药产线积累的全封闭管路、自动配液、自动分装、环境监控、SCADA/LIMS/MES联动能力,向病毒实验自动化工作站延伸。实现“无人/少人操作”。对于高等级生物安全实验和工艺开发,把“人进污染区”变为“数据进系统、设备做执行”。 四、底层逻辑:BT+AT+IT,构建生物先进制造技术壁垒 如果用三个关键词来概括赛动智造的底层路线,那就是:懂工艺、强执行、会思考。这背后正是 BT、AT 与 IT 的完美交织与深度赋能。 懂工艺,源于BT(生物技术与生命科学)的深厚积淀。我们精准拿捏细胞、病毒、核药等不同前沿品类的工艺差异与关键质量属性,让智造始终尊重生命科学的本质。 强执行,依托AT(自动化与流体控制)的硬核装备。凭借矩阵培养、姿态调控、智能配液、精密分装以及核药活度控制等核心技术,我们将复杂的生物工艺转化为标准化、高精度的工业动作,确保每一个物理环节都精准无误。 会思考,则来自IT(信息与人工智能)的智慧赋能。通过 MES 智能排产、LIMS 质检管理、数字孪生、全生命周期溯源、远程审计与智能决策系统,我们实现了生产全流程的透明化、合规化与最优化。 五、把企业成长写进国家战略,前沿疗法不再遥不可及 从先进制造看,赛动不是单纯卖装备,而是把细胞、核药、病毒实验三类高壁垒场景统一到“合规、可追溯、可复制、自主可控”的工业标准上: 对医院与科研机构,提供床边/中心化柔性产线,让临床研究不被制备产能卡脖子; 对创新企业与CDMO,提供共享智造与软件底座,降低CGT创业门槛; 对核药企业,提供国产分装与核药房自动化,保障同位素短半衰期下的高时效交付; 对监管与QA,提供全生命周期数据与远程审计,让“最严合规”变成系统能力而非人工加班。 智能化是手段,绿色化是底线,融合化是路径。赛动智造将以国家工程中心先进智造平台为依托,继续把人工智能、数字孪生、自动流体、质量溯源下沉到活细胞、放射性药物和病毒实验一线,让前沿疗法从“可能”变“可及”,以“生物+智造”硬实力服务制造强国与生命健康国家战略。 赛动智造·为生命,从容护航。  相关链接  […]
October 20, 2026

Fujian CDMO Platform of the National Engineering Center for the Cell Industry Launches, Opening a Clinical Research and Translation Pathway for New Biomedical Technologies

On 25 December 2025, the “High-Quality Development Conference for Maternal and Child Health” of the Fujian Maternity and Child Health Hospital was held in Fuzhou. As a key part of the conference, […]
October 20, 2026

Addressing Sterility, Quality Management and Radiation Safety: CellAuto’s “Three Swords” of Nuclear-Medicine Automation Provide a One-Stop Intelligent Answer

Radiopharmaceutical manufacturing has to satisfy three demanding regulatory dimensions at once: sterile production, total quality management, and radiation safety. CellAuto’s “three swords” of nuclear-medicine automation — the Fully-Automatic Dispensing System, the Intelligent […]
October 20, 2026

Under Lecheng’s New Rules, How Can Cell Projects Localise On Time and Stay Compliant? CellAuto Offers a Practical Solution

Boao Lecheng has recently opened public consultation on its “Detailed Rules for the Suspension and Exit of the Translational Application of New Biomedical Technologies (Draft for Comment)”. The core signal is clear: […]
October 20, 2026

CellAuto Safeguards China’s First Approved Stem-Cell Clinical Application for Type-2 Diabetes with a Fully-Automated, Compliant Manufacturing System

On 21 March 2026, the launch event for the “New Paradigm Technology and Clinical Application Project for Stem-Cell Treatment of Type-2 Diabetes” was held in Hainan’s Boao Lecheng International Medical Tourism Pilot […]
October 20, 2026

Indonesian Stem-Cell Delegation Visits the National Engineering Center for the Cell Industry to Explore New Belt and Road Biomedical Cooperation

On 7 April 2026, Dr Lestari Poediastoeti Indah, a leading figure in stem-cell research in Indonesia, led a delegation on a visit to the National Engineering Research Center for Key Generic Technologies […]
October 20, 2026

Officially Certified: Beike Biotechnology (Qionghai) Passes Lecheng’s First Laboratory Compliance Inspection, with CellAuto’s Fully-Automated Cell Manufacturing Platform Recognised as GMP-Compliant

Editor’s note Congratulations to Beike Biotechnology! In April 2026, the Medical Products Administration of the Boao Lecheng International Medical Tourism Pilot Zone conducted on-site compliance inspections of 17 relevant laboratories in the […]
October 20, 2026

CellAuto’s AI Cell-Monitoring Platform: A Pioneering Model for the National “AI + Drug Regulation” Strategy

The recently released “Implementation Opinions on AI + Drug Regulation” (the “Opinions”) from China’s National Medical Products Administration set out an ambitious blueprint for the intelligent upgrading of drug regulation, with core […]
October 20, 2026

CellAuto Drives Biomanufacturing Upgrade Through Production-Line Transformation, Advancing the National Intelligent Manufacturing Strategy

At the recent National Advanced Manufacturing Conference, important instructions from General Secretary Xi Jinping were conveyed, stressing the need to stay the course on intelligent, green and integrated development, to keep making […]